logo

Soligenix, Inc. (SNGX)



Trade SNGX now with
  Date
  Headline
6/22/2021 7:45:21 AM HyBryte Says Positive Pivotal Phase 3 FLASH Study Selected For Presentation At USCLC Annual Meeting
6/10/2021 7:32:39 AM Soligenix Gets Pediatric Investigational Plan Waiver From EMA For HyBryte In Cutaneous T-cell Lymphoma
5/20/2021 7:40:38 AM Soligenix Gets Japanese Patent For Improved Production Of Synthetic Hypericin Composition
5/17/2021 7:34:58 AM Soligenix Q1 Net Loss $2.4 Mln Or $0.06/shr Vs. Net Loss $7.6 Mln Or $0.32/shr Last Year
4/26/2021 7:26:00 AM Soligenix Presents HyBryte Expanded Efficacy And Safety Data At American Academy Of Dermatology Meeting
4/7/2021 7:11:53 AM Soligenix Gets Conditional FDA Acceptance Of Proposed Brand Name HyBryte For SGX301 In CTCL
3/30/2021 7:14:33 AM Soligenix FY Basic Net Loss $17.7 Mln Or $0.64/Shr Vs Loss $9.4 Mln Or $0.48/Shr Last Year
3/4/2021 7:16:30 AM Soligenix Announces Positive Progress In Pre-clinical Development Of COVID-19 Vaccine
1/7/2021 7:18:35 AM Soligenix Inks Deal With Daavlin For Supply Of SGX301 Companion Light Device In Cutaneous T-Cell Lymphoma
12/28/2020 7:07:26 AM Soligenix Reports $1.5 Mln NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development
12/22/2020 6:34:46 AM Soligenix Phase 3 DOM-INNATE Study Fails To Meet Primary Endpoint Of Median Duration